S. Chiappetta

发表

HIV-1 Tropism Test Evaluation: Assessment and Clinical Implications

A. Lazzarin, G. Tambussi, S. Nozza, 2014 .

Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial.

A. Lazzarin, L. Galli, A. Cossarizza, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Impact of surgical timing on survival in patients with infective endocarditis: a time-dependent analysis

E. Agricola, M. de Bonis, R. Pasciuta, 2021, European Journal of Clinical Microbiology & Infectious Diseases.

The use of circulating cathodic antigen rapid test and serology for diagnosis of active Schistosoma mansoni infection in migrants in Italy, a non-endemic country: a cross sectional study

A. Lazzarin, L. Galli, A. Castagna, 2017, Memorias do Instituto Oswaldo Cruz.

Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study.

O. Alfieri, J. Přeček, C. Giannattasio, 2019, European heart journal.

Neurological manifestations in patients hospitalized with COVID‐19: A retrospective analysis from a large cohort in Northern Italy

R. Fumagalli, F. Colombo, P. Tarsia, 2020, The European journal of neuroscience.

Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.

A. Lazzarin, A. Antinori, F. Mazzotta, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine.

A. Lazzarin, L. Galli, A. Castagna, 2014, The new microbiologica.

Surgery and outcome of infective endocarditis in octogenarians: prospective data from the ESC EORP EURO-ENDO registry

John M. Hancock, O. Alfieri, J. Přeček, 2022, Infection.

Levels of Soluble Endothelial Protein C Receptor Are Associated with CD4+ Changes in Maraviroc-Treated HIV-Infected Patients

E. Faioni, C. Razzari, G. Tambussi, 2012, PloS one.

Surgery and outcome of infective endocarditis in octogenarians: prospective data from the ESC EORP EURO-ENDO registry

O. Alfieri, J. Přeček, C. Giannattasio, 2022, Infection.

Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients

M. Frigerio, M. Puoti, L. Belli, 2020, Journal of Infection.

Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients.

A. Lazzarin, G. di Perri, A. Calcagno, 2013, Journal of Antimicrobial Chemotherapy.

Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.

G. Tambussi, S. Nozza, M. Ripa, 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Immunosenescence and hurdles in the clinical management of older HIV-patients

G. Tambussi, M. Ripa, S. Chiappetta, 2017, Virulence.

Mild Course of SARS-CoV-2 Infection in a Liver Transplant Recipient Undergoing Plasma Exchange and Defibrotide for Acute Graft Rejection.

C. Perno, M. Puoti, L. Belli, 2021, Transplantation.

Soluble endothelial protein C receptor (sEPCR) as an inflammatory biomarker in naive HIV-infected patients during ART.

A. Lazzarin, L. Galli, V. Longo, 2016, The Journal of antimicrobial chemotherapy.

Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response.

A. Lazzarin, L. Galli, A. Castagna, 2017, The Journal of antimicrobial chemotherapy.

Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection

A. Lazzarin, L. Galli, A. Castagna, 2017, The Journal of antimicrobial chemotherapy.

Immunological Recovery After 24 Weeks of Antiretroviral Therapy in Patients With X4 Virus During Primary HIV Infection

A. Lazzarin, M. Clementi, L. Galli, 2014, Journal of acquired immune deficiency syndromes.

Beneficial Effects of cART Initiated during Primary and Chronic HIV-1 Infection on Immunoglobulin-Expression of Memory B-Cell Subsets

A. Lazzarin, G. Scarlatti, M. Tolazzi, 2015, PloS one.

Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients.

A. Lazzarin, G. di Perri, A. Calcagno, 2014, The Journal of antimicrobial chemotherapy.

Maraviroc 150 mg QD plus lopinavir/ritonavir, a NRTI‐sparing regimen for HIV‐infected naïve patients: 48‐weeks final results

A. Lazzarin, A. Antinori, L. Galli, 2012 .

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir

A. Lazzarin, F. Mazzotta, L. Galli, 2010, Journal of the International AIDS Society.

Neurological manifestations in patients hospitalized with COVID‐19: A retrospective analysis from a large cohort in Northern Italy

R. Fumagalli, F. Colombo, P. Tarsia, 2021, The European journal of neuroscience.